Hainan's Boao Lecheng zone: legal early access to drugs China hasn't approved yet
A special zone on a tropical island where FDA/EU/Japan-approved drugs and devices can be used before national China approval. What it is, who it's for, and its limits.
On the east coast of Hainan island, next to the Boao conference town, there is a special medical zone where the normal rule — "a drug must be approved in China to be used in China" — is deliberately relaxed. It is the Boao Lecheng International Medical Tourism Pilot Zone (博鳌乐城国际医疗旅游先行区), and for some patients it is the single most useful thing to know about Chinese healthcare.
The one-sentence version
In licensed institutions inside Lecheng, drugs and medical devices that are already approved by top overseas regulators (FDA, EMA, Japan's PMDA and others) but not yet approved in China can be legally imported and used on patients — years before they clear national China registration.¹
That is the opposite of the Greater Bay Area connect, which is for Hong Kong/Macao-marketed drugs. Lecheng is for globally-approved, China-pending products.
Why it exists
Set up by State Council approval (the zone dates to 2013, with the special-access policies layered on afterward), Lecheng was designed as a controlled experiment in faster access. It runs on a set of "special permission" policies — special-permission medical use, operation, research, and international exchange — that together let the zone act as a legal on-ramp for cutting-edge medicine.
The clever part is the real-world data loop: because these overseas drugs and devices are actually used on patients in Lecheng under monitoring, the clinical data generated there can be fed back into the national approval process. Some products have reached full China approval faster because of evidence gathered in Lecheng. It is a genuine regulatory innovation, not just a tourism gimmick.
What's actually available
By the zone's own reporting, several hundred special-access drugs and devices have been used there — a figure often cited around 485+ — spanning oncology, rare disease, ophthalmology, and advanced device categories. Roughly a few dozen medical institutions operate inside the zone.
Reported patient volume has been climbing: on the order of ~9,300 overseas patients in 2025 from around 14 countries, and in 2026 the zone stood up an international medical tourism service center to coordinate foreign patients.
Who it's for
- Patients who need a specific drug or device that is approved abroad but still pending in China — and who cannot wait for national approval.
- Common real cases: newer oncology drugs, rare-disease therapies, advanced ophthalmology (some specialized lenses and treatments have been Lecheng signatures), and cutting-edge devices.
- If your drug is already approved in mainland China, you do not need Lecheng — you can get it at a regular hospital, usually much closer and cheaper.
The limits and the honest caveats
- Use is inside the zone. Like the GBA connect, this is treat-here access under institutional supervision, not an import-and-ship scheme.
- It is self-pay, and not cheap. These are the newest therapies on earth; Lecheng removes the approval barrier, not the price barrier. Some Chinese commercial insurers have built Lecheng-specific coverage, but a foreign visitor should assume self-pay unless their insurer says otherwise.
- Access is clinical, not retail. You need a diagnosis and a treating institution inside the zone; you cannot simply show up and shop.
- Verify the specific product before you travel. Availability changes as products cycle in (and graduate to national approval). Confirm your exact drug/device with a Lecheng institution first.
How to use it
- Confirm your drug/device is approved overseas but not yet in mainland China (if it is already approved in China, skip Lecheng).
- Contact a licensed institution inside Lecheng to confirm they offer it and will accept you.
- Arrange the clinical referral and records; plan for self-pay.
- Treat Lecheng and the GBA connect as two different keys: Hainan for globally-approved/China-pending, the Bay Area for Hong Kong/Macao-marketed.
Sources & verification status
- Special-access mechanism (overseas-approved, China-pending drugs/devices usable in-zone) and the real-world-data-to-national-approval pathway: Boao Lecheng zone official policy framework. Regulator list, establishment year/approving body, and legal wording pending verification against the zone authority's primary pages.
- Scale figures — ~485+ special-access products, institution count, ~9,300 overseas patients/2025 from ~14 countries, 2026 service center